Mesoblast (AU: MSB)

Currency in -

Last close As at 26/05/2023

-0.93

0.23 (32.86%)

Market capitalisation

605m

Edison Investment Research is terminating coverage on Mesoblast. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare

Mesoblast: Edison Open House Healthcare 2022

Healthcare

Mesoblast — A significant impact on back pain

Healthcare

Mesoblast – Edison Open House interview

Healthcare

Mesoblast — Novartis licenses ARDS program

Sector

Healthcare

Balance Sheet

Forecast net cash (US$m)

16.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 36.8 (12.3) (53.5)
Relative 27.6 (7.6) (50.0)
52 week high/low A$2.0/A$0.6

Financials

Edison Investment Research is terminating coverage on Mesoblast. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2020A 31.6 (64.8) (79.6) (13.28) N/A N/A
2021A 7.4 (89.3) (104.3) (17.09) N/A N/A
2022E 8.6 (83.2) (92.6) (14.29) N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

Healthcare

Mesoblast — Waiting for readouts

Healthcare

Mesoblast — Confident management

Healthcare

Mesoblast — Update 28 February 2017

Healthcare

Mesoblast — Update 21 September 2016

Healthcare

Mesoblast — Update 8 July 2016

Healthcare

Mesoblast — Update 11 May 2016

Healthcare

Mesoblast — Update 17 February 2016

Healthcare

Mesoblast — Update 24 January 2016

Healthcare

Drug delivery platforms

Healthcare

Neuroscience comeback

Consumer

IPO apocalypse

TMT

ESG, moving beyond the box tick

Healthcare

Artificial intelligence in drug discovery

Healthcare

Edison Exhibits- antibiotic development

Healthcare

The next wave in AMD

Healthcare

Cannabinoid Therapies- The coming retail wave

Healthcare

The diagnostics sector

Healthcare

ASCO 2017